Free Trial

Biogen (BIIB) Earnings Date, Estimates & Call Transcripts

Biogen logo
$146.47 -0.92 (-0.62%)
(As of 12/20/2024 05:45 PM ET)

Biogen Latest Earnings Summary

Actual EPS
(Oct. 30)
$4.08 Beat By $0.31
Consensus EPS
(Oct. 30)
$3.77

Biogen announced Q3 2024 earnings on October 30, 2024, reporting an EPS of $4.08, which topped the consensus estimate of $3.77 by $0.31. Quarterly revenue fell 2.5% year-over-year to $2.47 billion, above analysts' expectations of $2.43 billion. With a trailing EPS of $11.07 and a P/E Ratio of 13.23, Biogen's earnings are expected to grow 2.50% next year, from $16.43 to $16.84 per share.

Get Biogen Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biogen and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

BIIB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BIIB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Biogen Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20244$3.25$3.54$3.34 
Q2 20244$3.43$4.12$3.91 
Q3 20244$3.38$3.80$3.65 
Q4 20244$3.26$3.42$3.33 
FY 202416$13.32$14.88$14.23 
Q1 20253$3.82$4.02$3.90 
Q2 20253$3.79$4.27$4.03 
Q3 20253$3.47$3.93$3.77 
Q4 20253$3.85$4.11$3.94 
FY 202512$14.93$16.33$15.64 
Q1 20261$3.78$3.78$3.78 
Q2 20261$4.45$4.45$4.45 
Q3 20261$4.64$4.64$4.64 

Biogen Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/30/2024Q3 2024$3.77$4.08+$0.31$5.50$2.43B$2.47B
8/1/2024Q2 2024$4.00$5.28+$1.28$6.56$2.39B$2.47B
4/24/2024Q1 2024$3.45$3.67+$0.22$4.64$2.31B$2.29B
2/13/2024Q4 2023$3.18$2.95 -$0.23$4.19$2.47B$2.39B
11/8/2023Q3 2023$3.99$4.36+$0.37$9.19$2.40B$2.53B
7/25/2023Q2 2023$3.77$4.02+$0.25$3.97$2.36B$2.46B
4/25/2023Q1 2023$3.25$3.40+$0.15$4.13$2.34B$2.46B
2/15/2023Q4 2022$3.48$4.05+$0.57$4.31$2.44B$2.54B

Biogen Earnings - Frequently Asked Questions

Biogen (NASDAQ:BIIB) last announced its quarterly earning data on Wednesday, October 30, 2024. Learn more on BIIB's earnings history.

Biogen updated its FY 2024 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of 16.100-16.600 for the period, compared to the consensus EPS estimate of 16.190. The company issued revenue guidance of -.

In the previous quarter, Biogen (NASDAQ:BIIB) reported $4.08 earnings per share (EPS) to beat the analysts' consensus estimate of $3.77 by $0.31. Learn more on analysts' earnings estimate vs. BIIB's actual earnings.

The conference call for Biogen's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Biogen's latest earnings report can be read online.
Read Transcript

Biogen's earnings report can be found in their filing with the SEC.
View SEC filing

Biogen (NASDAQ:BIIB) has a recorded annual revenue of $9.61 billion.

Biogen (NASDAQ:BIIB) has a recorded net income of $1.16 billion. BIIB has generated $11.07 earnings per share over the last four quarters.

Biogen (NASDAQ:BIIB) has a trailing price-to-earnings ratio of 13.23 and a forward price-to-earnings ratio of 8.91. The price/earnings-to-growth ratio is 1.83.

Biogen's earnings are expected to grow from $16.43 per share to $16.84 per share in the next year, which is a 2.50% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:BIIB) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners